Seven weeks before Merck Co. pulled the arthritis drug Vioxx off the market because of safety concerns, federal drug regulators downplayed the significance of scientific findings citing the increased risks, documents released Thursday show.
 The issue of drug advertising directly aimed at consumers was thrust into the news recently when Merck withdrew its arthritis painkiller Vioxx from the market, citing studies indicating a risk of heart attacks or strokes.
 Merck's decision to withdraw Vioxx cast suspicion on the safety of drugs in that class.